Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children

PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

July 1, 2019

Study Completion Date

August 7, 2019

Conditions
Schistosomiasis
Interventions
BIOLOGICAL

Sm14

Three 0.5 mL intra-muscular injections of the vaccine solution (50μg Sm14) will be administered on D0, W4, W8 (D = day, W = week).

DRUG

GLA-SE solution

The lot concentration 10μg/mL for injection of 2.5μg GLA-SE/injection.

Trial Locations (1)

BP226

Biomedical Research Center EPLS, Saint-Louis

All Listed Sponsors
collaborator

Orygen Biotecnologia SA

UNKNOWN

collaborator

Biomedical Research Center EPLS

OTHER

collaborator

Access to Advanced Health Institute (AAHI)

OTHER

lead

Oswaldo Cruz Foundation

OTHER

NCT03799510 - Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children | Biotech Hunter | Biotech Hunter